The 2023 Consolidated Appropriations Act removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe medications, like buprenorphine, for the treatment of opioid use disorder (OUD). Effective immediately, Substance Abuse and Mental Health Services Administration (SAMHSA) will no longer be accepting NOIs (waiver applications).
All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for OUD in their practice if permitted by applicable state law. SAMHSA encourages them to do so.
On December 29, 2022, the Consolidated Appropriations Act of 2023 enacted a new one-time requirement. Beginning June 27, 2023, DEA license holders, upon initial registration or renewal, will be required to complete at least eight hours of training in the treatment or management of patients with opioid or other substance use disorders.